PMID- 33528609
OWN - NLM
STAT- MEDLINE
DCOM- 20210305
LR  - 20210305
IS  - 1432-0584 (Electronic)
IS  - 0939-5555 (Linking)
VI  - 100
IP  - 3
DP  - 2021 Mar
TI  - Nivolumab discontinuation and retreatment in patients with relapsed or refractory 
      Hodgkin lymphoma.
PG  - 691-698
LID - 10.1007/s00277-021-04429-8 [doi]
AB  - Immune checkpoint inhibitors (ICI) have demonstrated high therapeutic efficacy in 
      relapsed or refractory classical Hodgkin lymphoma (r/r cHL). Nevertheless, 
      despite the accumulated data, the question of the ICI therapy duration and 
      efficacy of nivolumab retreatment remains unresolved. In this retrospective 
      study, in a cohort of 23 adult patients with r/r cHL who discontinued nivolumab 
      in complete response (CR), the possibility of durable remission achievement 
      (2-year PFS was 55.1%) was demonstrated. Retreatment with nivolumab has 
      demonstrated efficacy with high overall response rate (ORR) and CR (67% and 33.3% 
      respectively). At the final analysis, all patients were alive with median PFS of 
      16.5 months. Grade 3-4 adverse events (AEs) were reported in 36% of patients, and 
      there was no deterioration in terms of nivolumab retreatment-associated 
      complications.
FAU - Fedorova, Liudmila V
AU  - Fedorova LV
AUID- ORCID: 0000-0002-3275-219X
AD  - RM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russian 
      Federation. lucyfed3@gmail.com.
FAU - Lepik, Kirill V
AU  - Lepik KV
AD  - RM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russian 
      Federation.
FAU - Mikhailova, Natalia B
AU  - Mikhailova NB
AD  - RM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russian 
      Federation.
FAU - Kondakova, Elena V
AU  - Kondakova EV
AD  - RM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russian 
      Federation.
FAU - Zalyalov, Yuri R
AU  - Zalyalov YR
AD  - RM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russian 
      Federation.
FAU - Baykov, Vadim V
AU  - Baykov VV
AD  - RM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russian 
      Federation.
FAU - Babenko, Elena V
AU  - Babenko EV
AD  - RM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russian 
      Federation.
FAU - Kozlov, Andrey V
AU  - Kozlov AV
AD  - RM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russian 
      Federation.
FAU - Moiseev, Ivan S
AU  - Moiseev IS
AD  - RM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russian 
      Federation.
FAU - Afanasyev, Boris V
AU  - Afanasyev BV
AD  - RM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russian 
      Federation.
LA  - eng
PT  - Journal Article
DEP - 20210202
PL  - Germany
TA  - Ann Hematol
JT  - Annals of hematology
JID - 9107334
RN  - 31YO63LBSN (Nivolumab)
SB  - IM
MH  - Adult
MH  - Cohort Studies
MH  - Drug Administration Schedule
MH  - *Drug Resistance, Neoplasm/drug effects
MH  - Female
MH  - Hodgkin Disease/*drug therapy/*pathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Nivolumab/*administration & dosage/adverse effects
MH  - Recurrence
MH  - Retreatment
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Withholding Treatment
MH  - Young Adult
OTO - NOTNLM
OT  - Hodgkin lymphoma
OT  - Immune checkpoint inhibitors
OT  - Immune therapy
OT  - Nivolumab
OT  - Relapsed or refractory disease
EDAT- 2021/02/03 06:00
MHDA- 2021/03/06 06:00
CRDT- 2021/02/02 12:13
PHST- 2020/03/01 00:00 [received]
PHST- 2021/01/14 00:00 [accepted]
PHST- 2021/02/03 06:00 [pubmed]
PHST- 2021/03/06 06:00 [medline]
PHST- 2021/02/02 12:13 [entrez]
AID - 10.1007/s00277-021-04429-8 [pii]
AID - 10.1007/s00277-021-04429-8 [doi]
PST - ppublish
SO  - Ann Hematol. 2021 Mar;100(3):691-698. doi: 10.1007/s00277-021-04429-8. Epub 2021 
      Feb 2.